<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00618345</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000582257</org_study_id>
    <secondary_id>P30CA015083</secondary_id>
    <secondary_id>MC048E</secondary_id>
    <secondary_id>96-05</secondary_id>
    <nct_id>NCT00618345</nct_id>
  </id_info>
  <brief_title>Everolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma</brief_title>
  <official_title>Phase II Trial of RAD001 in Relapsed/Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Everolimus may stop the growth of cancer cells by blocking some of the enzymes&#xD;
      needed for cell growth and by blocking blood flow to the cancer.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well everolimus works in treating patients with&#xD;
      relapsed or refractory multiple myeloma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To assess the response rate in patients with relapsed or refractory multiple myeloma&#xD;
           treated with everolimus.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To evaluate the toxicity of everolimus in patients with multiple myeloma.&#xD;
&#xD;
        -  To study the tumor cells and blood from patients entering this trial for laboratory&#xD;
           correlates.&#xD;
&#xD;
      OUTLINE: Patients receive oral everolimus once daily on days 1-28. Treatment repeats every 4&#xD;
      weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients undergo bone marrow aspirate, biopsy, and blood sample collections periodically.&#xD;
      Samples are assessed for the following: cyclin D1, phospho-AKT, phospho-p70 S6 kinase, and&#xD;
      phospho-S6 by western blot; checkpoint regulators PTEN, p53, pRB, and p27 by immunoblotting;&#xD;
      p53, Rb, p16, PTEN, p27, and cyclin D1 by DNA analysis; caspases 3 and 9 by immunoblotting&#xD;
      and Annexin/PI by flow cytometry; unknown molecular markers by protein profiling; and&#xD;
      microvessel density.&#xD;
&#xD;
      After completion of study treatment, patients are followed every 3-6 months for up to 2&#xD;
      years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2005</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">October 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Confirmed response (complete response, very good partial response, partial response, or minimal response) of serum and urine monoclonal protein</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>everolimus</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>DNA analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>protein analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>western blotting</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>flow cytometry</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>biopsy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of multiple myeloma, meeting 1 of the following criteria:&#xD;
&#xD;
               -  Monoclonal protein in the serum of ≥ 1 g/dL&#xD;
&#xD;
               -  Monoclonal light chain in the urine protein electrophoresis of ≥ 200 mg/24 hours&#xD;
&#xD;
               -  Measurable light chains by free light chain assay of ≥ 10 mg/dL&#xD;
&#xD;
               -  Measurable plasmacytoma&#xD;
&#xD;
          -  Must have received prior therapy and have relapsed or refractory disease&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Life expectancy ≥ 12 weeks&#xD;
&#xD;
          -  ANC ≥ 1,000/mm³&#xD;
&#xD;
          -  Platelet count ≥ 75,000/mm³&#xD;
&#xD;
          -  Hemoglobin ≥ 8.0 g/dL&#xD;
&#xD;
          -  Total bilirubin ≤ 2.0 mg/dL (if total bilirubin is elevated, direct bilirubin must be&#xD;
             normal)&#xD;
&#xD;
          -  AST ≤ 3 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Creatinine ≤ 1.5 times ULN&#xD;
&#xD;
          -  Calcium &lt; 11 mg/dL&#xD;
&#xD;
          -  No uncontrolled infection&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No HIV positivity&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 3 weeks since prior cytotoxic chemotherapy&#xD;
&#xD;
          -  At least 2 weeks since prior biologic therapy or radiotherapy&#xD;
&#xD;
          -  At least 2 weeks since prior corticosteroids&#xD;
&#xD;
               -  Concurrent chronic corticosteroids allowed for treatment of disorders other than&#xD;
                  myeloma&#xD;
&#xD;
          -  No other concurrent chemotherapy, immunotherapy, radiotherapy, or any ancillary&#xD;
             therapy considered investigational&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas E. Witzig, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rafael Fonseca, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Roy Vivek, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <verification_date>May 2011</verification_date>
  <study_first_submitted>February 19, 2008</study_first_submitted>
  <study_first_submitted_qc>February 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 20, 2008</study_first_posted>
  <last_update_submitted>May 13, 2011</last_update_submitted>
  <last_update_submitted_qc>May 13, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 16, 2011</last_update_posted>
  <responsible_party>
    <name_title>Thomas E. Witzig, M.D.</name_title>
    <organization>The Mayo Clinic</organization>
  </responsible_party>
  <keyword>refractory multiple myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

